- News & Research
- Corporate Actions
- CBONDS OLD
Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
|10/06/2021||Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021|
|08/06/2021||Fitch Ratings withdrew LT Int. Scale (foreign curr.) credit rating for Bristol Myers Squibb|
|08/06/2021||Fitch Ratings revised outlook on Bristol Myers Squibb to stable and affirmed at "A-" (LT Int. Scale (foreign curr.)) credit rating|
|05/02/2021||Moody's Investors Service revised outlook on Bristol Myers Squibb to stable and affirmed at "A2" (LT- foreign currency) credit rating|